Addex Therapeutics (SIX:ADXN), (NASDAQ:ADXN) is a research-focused company dedicated to discovering and developing oral small molecule therapeutic agents. With a keen focus on allosteric modulators for neurological disorders, Addex's projects primarily revolve around innovative treatments for epilepsy, Parkinson's disease, and other central nervous system (CNS) conditions. The company harnesses its proprietary discovery platform to uncover drugs with the potential to offer improved efficacy and safety profiles compared to existing options. Among its notable assets, Addex is actively advancing a diverse pipeline that includes its flagship programs targeting negative allosteric modulators (NAMs) of the metabotropic glutamate receptor 5 (mGluR5) for the treatment of movement disorders and its GLP-1R program aimed at addressing metabolic disorders. The overarching objective of Addex is to contribute meaningful advancements in the CNS therapeutic area, striving to improve the lives of patients dealing with challenging neurological disorders.